Pfizer Inc applied for the reissue patent in January 2007, to correct a technical defect in the ‘995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.
According to Pfizer Inc's announcement, the U.S. Patent & Trademark Office has issued a “Notice of Allowance” accepting Pfizer Inc’s application to correct a technical defect in the ‘995 patent.
The reissue patent will have the same force and effect as the original ‘995 patent and the same June 2011 expiration date.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지